The emergence of extensively drug-resistant (XDR) and multidrug-resistant (MDR) pathogens and the dearth of novel medicines that are effective against these bacteria provide two key challenges to the treatment of bacterial diseases. Consequently, physicians in present days have reverted to usingtraditional antibiotics such as aminoglycosides, tetracyclines, and polymyxins. Lately, due to the development of resistance to these agents as well, the broad-spectrum antibacterial agent, Fosfomycin has gained attention. It is a low-molecular-weight, bactericidal, broad-spectrum antibiotic, with activity against Gram-positive and Gram-negative multidrug-resistant bacteria. Fosfomycin, an older drug with well -established safety profile, has experienced a rise in application for various infections, such as chronic bacterial prostatitis (CBP) and chronic pelvic pain syndrome (CPPS). However, despite its broad application, there is a lack of well-designed clinical trials supporting various uses. As a result, there is a need for more robust data to validate its efficacy, optimal dosing, and treatment duration, particularly considering much of the current information comes from public domain sources rather than rigorous scientific research.In this review, we summarize the available susceptibility data on Fosfomycin, focusing on current trends in its clinical use, its pharmacokinetic and pharmacodynamic properties, its activity against susceptible and antibiotic-resistant bacteria, its synergistic effects with other antibiotics, and its overall clinical effectiveness in treating urinary tract infections. The dosing guidelines for Fosfomycin and adverse events caused by this agent are also presented in this review.